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Received 16 November 2009; accepted 27 November 2009Abstract Recent withdrawals of prescription drugs from clinical use because of unexpected side effects on the heart have
highlighted the need for more reliable cardiac safety pharmacology assays. Block of the human Ether-a-go go Related Gene
(hERG) ion channel in particular is associated with life-threatening arrhythmias, such as Torsade de Pointes (TdP). Here we
investigated human cardiomyocytes derived from pluripotent (embryonic) stem cells (hESC) as a renewable, scalable, and
reproducible system on which to base cardiac safety pharmacology assays. Analyses of extracellular field potentials in hESC-
derived cardiomyocytes (hESC-CM) and generation of derivative field potential duration (FPD) values showed dose-dependent
responses for 12 cardiac and noncardiac drugs. Serum levels in patients of drugs with known effects on QT interval overlapped
with prolonged FPD values derived from hESC-CM, as predicted. We thus propose hESC-CM FPD prolongation as a safety criterion
for preclinical evaluation of new drugs in development. This is the first study in which dose responses of such a wide range of
compounds on hESC-CM have been generated and shown to be predictive of clinical effects. We propose that assays based on
hESC-CM could complement or potentially replace some of the preclinical cardiac toxicity screening tests currently used for
lead optimization and further development of new drugs.
© 2009 Elsevier B.V. All rights reserved.Introduction
The pharmaceutical industry currently generates large
libraries of “new chemical entities” (NCEs) with the aim of
selecting those most promising for clinical trials. Distinguish-
ing specific from detrimental off-target effects at an early
stage has the potential to accelerate clinical introduction,
improve drug safety, and reduce drug development costs.⁎ Corresponding author. Fax: +31 71 526 8289.
E-mail address: c.l.mummery@lumc.nl (C.L. Mummery).
1873-5061/$ – see front matter © 2009 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2009.11.004The heart has proven to be particularly sensitive to off-
target, life-threatening toxic effects of noncardiac drugs.
Over the past several years, reports of unexpected drug-
induced ventricular arrhythmias associated with sudden
cardiac death have led to the withdrawal of a number of
drugs from the market, while for many others, additional
safety labels have been required to warn of potential risk
(Redfern et al., 2003).
An important determinant for development of Torsade de
Pointes (TdP) is prolongation of the QT interval indicating
delayed ventricular repolarization. This is defined as the
period between the beginning of the QRS complex (depolar-
ization of the ventricles) and the end of the T-wave
(repolarization of the ventricles) on an electrocardiogram.
108 S.R. Braam et al.(ECG). In 1998 the Food and Drug Administration (FDA)
defined prolongation of the QT interval on an ECG as a major
drug safety issue. Currently, assessing risk for QT interval
prolongation is part of the standard preclinical evaluation of
NCEs as defined by the International Conference of Harmo-
nization (ICH) Expert Working Group in topic S7B for all drugs
in development (Bode and Olejniczak, 2002; Cavero and
Crumb, 2005).
Drug-induced long QT is most commonly induced by
affecting the rapid potassium current Ikr by binding to the
hERG ion channel (Moss and Kass, 2005; Roden et al., 1996).
For both cardiac and noncardiac drugs, primary canine or
rabbit Purkinje fibers or cell lines ectopically expressing the
hERG ion channel are the preclinical in vitro test systems
currently available. Species differences, or the lack of
complex ion channel interactions in transgenic cell lines,
reduce the predictive value of these systems. For example,
determination of the IC50 value for a drug compound in
transgenic cell lines oversimplifies a complex process that is
state, time, and voltage dependent. Some drugs like
dofetilide require channel activation to reduce the hERG
current (Weerapura et al., 2002), while others, like
fluvoxamine, interact exclusively with a closed channel.
Finally, not all drugs that block hERG channels in these cell
systems carry an arrhythmogenic risk; one well-known
example is verapamil (Redfern et al., 2003). Also of note:
many antiarrhythmics can interact with multiple ion chan-
nels simultaneously. In addition to potassium channels, the
activity of a heart cell is largely dependent on sodium and
calcium channels. Whereas activation of sodium channels is
required for the generation of an action potential, inward
Ca2+ currents through (L-type) calcium channels counterbal-
ance outward potassium currents in the repolarization
phase. To illustrate the complexity of predicting QT
prolongation, a recent comparison of 10 drugs on dog
Purkinje fibers demonstrated a wide range of effects on QT
time, ranging from 158% prolongation to 16% shortening,
while all compounds blocked hERG channels by more than
50% (Martin et al., 2004).
Together, these findings emphasize the importance of
assessing preclinical cardiotoxic responses to drugs on cells
that closely resemble functional cardiomyocytes of the
human heart. Moreover, any alternatives to the current
models must be scalable, reproducible, and preferably from
an inexhaustible source. Human embryonic stem cell-derived
cardiomyocytes (hESC-CMs) have this potential (Denning and
Anderson, 2008). Embryonic stem cells can differentiate to
all somatic cell types including cardiomyocytes and in recent
years, much effort has been put into developing efficient and
reproducible differentiation protocols (Passier and Mummery,
2005) and methods for cardiomyocyte enrichment from
differentiated cell populations (Anderson et al., 2007; Huber
et al., 2007; Xu et al., 2008). Here, we describe the use of
hESC-CM in a medium-throughput screening system using
microelectrode arrays (MEAs) to determine action potential
duration or QT interval by measuring extracellular field
potentials. We provide a first validation of the system, using
a selection of drugs previously associatedwithQTprolongation
and/or TdP during clinical use in humans. We show that hESC-
CM, as used here, can recapitulate drug toxicity mediated
through human ion channels and therefore represent an
opportunity for preclinical NCE evaluation.Results
Validation of hESC-CM
Coculture of HES2 and HES3 cells with visceral endoderm-like
END-2 cells is among the most efficient ways to produce
enriched cultures of hESC-CM (Mummery et al., 2003; Passier
and Mummery, 2005). Using an optimized serum- and insulin-
free protocol, cultures containing ∼25% cardiomyocytes can
be reproducibly obtained within 12 days of initiating
differentiation (Freund et al., 2007; Mummery et al., 2007;
Passier et al., 2005).
To test the cardioactivity of drugs, it is important that the
electrical properties of the target cell are known. We
therefore first analyzed action potentials of HES3-derived
cardiomyocytes using patch clamp electrophysiology, as
described previously (Mummery et al., 2003). Cells were
designated as ventricle-like, atrial-like, or pacemaker-like
based on the shape of the action potential (AP) defined by
the following parameters: amplitude, maximal repolariza-
tion, maximum increase in AP (dV/dtmax), AP duration
(APD90), and the overall pattern of the AP compared to
those recorded in cells from 16 week human fetal hearts (De
Sousa Lopes et al, 2006; Mummery et al., 2003). Ventricular-
like APs characteristically show a plateau phase that results
in longer repolarization compared to the more triangular
shaped, atrial-like APs. Pacemaker-like cells are character-
ized by slow upstroke velocities and smaller amplitudes.
As described previously for the HES2 cell line (Mummery
et al., 2003), cardiomyocytes generated from the HES3–END-
2 cocultures were almost exclusively ventricular-like
(Fig. 1a). An example of a typical action potential is shown
in Fig. 1b. We therefore concluded that these relatively
homogeneous populations of cardiac ventricular cells may be
particularly suitable for drug cardiotoxicity screening.
Traditional patch clamp electrophysiology, the most
accurate measure of the properties of electrically excitable
cells, requires precise positioning of the electrode on the
plasma membrane to enable gigaohm seals to form between
the electrode and the cell. However, this is labor intensive,
limited to individual cells, and therefore unsuitable for
medium/high-throughput drug screens. The more sophisti-
cated planar patch clamp systems are potentially suitable but
are difficult to implement since they require purified single
cell suspensions. Measurement of external field potentials
generated by clumps of beating cardiomyocytes derived from
hESC, rather as an electrocardiogram on patients, represents
an attractive alternative to conventional patch clamp
analyses of APs that is amenable to medium throughput
modalities. The signal recorded with one of the extracellular
electrodes integrated into the substrate reflects local
changes of themembrane potential in a cluster of electrically
connected cardiomyocytes (Figs. 1c–f). An example of a field
potential is shown in Fig. 1g. Parameters such as the field
potential duration (FPD) are easy to define and measure and
are directly linked to the action potential duration.
Drug effects on hESC-derived cardiomyocytes
To determine whether hESC-CM would be a useful model for
detecting drug-induced QT elongation we first profiled field
Figure 1 Experimental setup. (a) Patch clamp analyses of cardiac differentiated HES3 cells. (b) Example of a ventricular-like action
potential measured by patch clamp electrophysiology. (c) Multichannel electrode chip with culture chamber. (d) Six-well
multichannel electrode chip for higher throughput. (e) Example of hESC-derived cardiomyocytes attached and cultured on a MEA chip.
(f) Amplifier used for digitizing electrical signals recorded by one of the electrodes. (g) Example of a hESC-CM field potential.
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Lidocaine was used to block INa, nifidipine to block ICaL, and E-
4031 for IKr. As expected, lidocaine did not affect the FPD in
three independent experiments; however, it caused cessation
of beating in the 30–100 μM concentration range (data not
shown). This is in agreement with a published INa IC50 for
lidocaine of 61 μM (Hill et al., 1989) and with a study of Satin et
al., who described initiation of the spontaneous action
potentials in hESC-CMby the sodiumcurrent (Satin et al., 2004).
Nifidipine, a typical L-type calcium channel blocker,
reproducibly induced a dose-dependent shortening of the
FPD, which was initiated at 10 nM and saturated at 1 μM in
three independent experiments (Figs. 2c and d). In 3 out of 4
independent experiments loss of spontaneous activity was
observed between 300 nM and 1 μM, indicating the
importance of a strong inward calcium current for cyclic
contraction. Concomitant with decreased FPD, we observed
a higher beating frequency but no arrhythmic behavior.
E-4031 is a specific blocker of the hERG channel. In four
independent experiments E-4031 induced sustained prolonga-
tion of the FPD at concentrations of 30 nM and higher (Figs. 2e
and f).At concentrationsof 1–3μM,early after-depolarizations
(EADs), which indicate an increased tendency for arrhythmia,
were observed in 3 out of 4 experiments (data not shown).
Beating frequency was not affected at nanomolar concentra-
tions; however, at higher concentrations it was reduced,
indicating a concomitant nonspecific ion-channel block.
Responses to repolarization-prolonging
antiarrhythmic drugs
A large class of cardioactive drugs is used clinically to treat
arrhythmias. These drugs are classified in four categoriesand, except for category II (beta-adrenergic receptor-
blocking), their mechanism of action is related to ion-
channel block. We tested two compounds, quinidine (class
Ia) and D,L-sotalol (Classes II and III) for their effects on field
potential profiles. Quinidine administration to patients is
strongly associated with TdP (1-8.8%) (Redfern et al., 2003).
In hESC-CM it induced a dose-dependent FPD prolongation
(Fig. 3a). At the estimated unbound therapeutic plasma
concentration (ETPC unbound) which is 0.9–3.2 μM, we
observed a 20–50% increase in QT time which was further
prolonged at higher concentrations. D,L-sotalol administra-
tion to patients is also strongly associated with TdP (1.8–
4.8%); it also induced a dose-dependent FDP prolongation in
hESC-CM. At the ETPC unbound (1.8–14 μM) we observed a
15–20% FPD prolongation, which increased at higher con-
centrations (Fig. 3b). In summary, both drugs prolonged
the FPD at physiologically relevant plasma concentrations,
as expected.
Responses to noncardiac drugs associated with TdP
or QT prolongation
In addition to repolarization-prolonging antiarrhythmic
drugs, where QT prolongation is the desired effect, a large
class of (noncardiac) drugs prolongs the QT interval as a
detrimental side effect. These drugs derive from various
therapeutic areas and include but are not limited to
antihistamines, antipsychotics, and antimicrobial agents.
Here we tested cisapride, sparfloxin, terfenadine, domper-
idone, and sertindole, all of which are associated with QT
prolongation and/or TdP as a side effect. Although the
clinical incidence of TdP for all of these drugs is low,
cisapride and terfenadine have been withdrawn from the
Figure 2 Validation of hESC-CM field potential responses. (a) Sodium peak amplitude–dose relationship for hESC-CM in the presence of increasing amounts of lidocaine. (b) Example
of field potential raw data; note the reduction of amplitude at higher concentrations. (c) FPD–dose relationship for hESC-CM in the presence of increasing amounts of nifidipine. (d)
Example of field potential raw data; note the reduction of field potential duration at higher concentrations of nifidipine. (e) FPD–dose relationship for hESC-CM in the presence of






Figure 3 Drug responses of repolarization-prolonging antiar-
rhythmia. FPD–dose relationship for hESC-CM in the presence of
increasing amounts of (a) quinidine, and (b) D,L-sotalol. The
gray areas indicate the ETPC unbound measured in patients and
the black line indicates hERG IC50. Dotted lines indicate the 95%
confidence interval of the fitted curve. ETPC unbound and hERG
IC50 data are adapted from Redfern et al., 2003.
111Cardiotoxicity prediction using human stem cellsmarket because of negative risk/benefit analyses. Cisapride
is a serotonin 5-HT4 agonist which increases acetylcholine
release in the enteric nervous system and was used for the
treatment of a number of gastrointestinal disorders, partic-
ularly gastro-esophageal reflux disease in adults and chil-
dren. In a market span of 12 years, 384 cases of ventricular
arrhythmias due to TdP were reported, giving a TdP
incidence of 1/120 000 (Darpo, 2001). The ETPC unbound is
2.6–4.9 nM (Redfern et al., 2003). At this concentration we
observed no effects on the FPD (Fig. 4a). However, at higher
concentrations sustained prolongation of the FDP was
observed (Fig. 4a).
Sparfloxacin is an antibiotic used for the treatment of
bacterial infections. The ETPC unbound is 0.19–1.76 μM
which overlaps with published IC50 values (0.23–34.4 μM).
This would classify sparfloxacinwith repolarization-prolonging
antiarrhythmics in a conventional hERG assay. However, in
integrated safety analysis of data from 6 multicenter phase III
trials, QTc (heart rate corrected QT interval) prolongation
(10±24 ms) occurred in 1.1% of the patients. There were no
ventricular arrhythmias related to QTc prolongation in any of
these patients (Lipsky et al., 1999). In hESC-CM we found no
FDP prolongation at the ETPC unbound but only at higher
concentrations (Fig. 4b), thus supporting the toxicity screening
potential of the hESC-CM model as used here. Terfenadine, an
antihistamine used for the treatment of allergies, is a“prodrug” and generally metabolized to the active form
fexofenadine by intestinal CYP3A4. The association with TdP is
low with an occurrence of once in 10 000 person years.
Nevertheless the compound has been withdrawn from the
market due to perceived risks. The ETPC unbound is 0.1–
0.29 nM. However, in cases of genetic deficiencies or induced
CYP3A4 inhibition (e.g., grapefruit juice or erythromycin)
terfenadine concentrations in human plasma may reach
100 nM (Roy et al., 1996). At this higher concentration, we
observed 10% FPD prolongation (Fig. 4c). At even higher
concentrations, we observed a further increase, followed by a
dose-dependent reduction of FPD at micromolar concentra-
tions. The shortening is most likely a result of calcium channel
block (Liu et al., 1997). Domperidone is an antidopaminergic
drug administrated orally, rectally, or intravenously to
suppress nausea and vomiting. TdP has been reported
sporadically and solely with intravenous use (Drolet et al.,
2000; Osborne et al., 1985). The ETPC unbound is 5–19 nM; at
this concentration there is only aminor prolongation of the FPD
(Fig. 4d). At higher concentrations, however, there is a
biphasic dose-dependent FPD prolongation that suggests
block of multiple channels (Fig. 4d).
Finally we tested the effects of sertindole. Sertindole is a
drug used for the treatment of schizophrenia but was
withdrawn from the market in 1998 after concern on the
high rate of proven or suspected TdP. After reevaluation of
existing data and new clinical data, sertindole was reintro-
duced to the European market in 2002 (Lindstrom et al.,
2005). We did not observe FDP prolongation at the ETPC
unbound (0.02–1.59 nM) and even at higher concentrations,
only a relatively weak FPD prolongation was observed (Fig.
4e). In summary, all of these compounds showed effects on
the FPD interval, although in general, this was at concentra-
tions higher than the ETPC unbound. This correlates well
with the overall very low incidence of TdP induced by these
drugs. In general, for these drugs a wide safety margin
between plasma concentrations and side effects on cardio-
myocytes would be advisable. Induction of TdP due to
overdosing or disturbed metabolism (see, for example,
terfenadine) is not acceptable and has led to numerous
drug failures.
Responses to drugs not associated with TdP in man
Next we investigated two drugs not clinically associated
with QT prolongation or TdP (as negative controls).
Ketoconazole is a drug used to treat a variety of fungal
infections and there is no evidence that it causes TdP or QT
prolongation. However, ketoconazaole is a strong inhibitor
of cyp34a and may therefore be involved in drug–drug
interactions associated with TdP (for example, terfena-
dine). We observed no FPD prolongation in hESC-CM in the
concentration range of 0.3 nM–30 μM, as expected (Fig.
5a). Verapamil is a class IV antiarrhythmic used clinically to
treat atrial tachyarrhythmias. The compound exerts its
action by blocking calcium channels but is also a potent
hERG blocker. In fact the narrow safety margin between the
ETPC unbound (25–81 nM) and the hERG IC50 (140–830 nM)
would make this compound a false positive in conventional
hERG assays (Redfern et al).
At the ETPC unbound concentration (25–81 nM) we
observed a minor FPD shortening which was amplified at
Figure 4 hESC-CM responses to drugs associated with QT prolongation or TdP. FPD–dose relationship for hESC-CM in the presence of
increasing amounts of (a) cisapride, (b) sparfloxacin, (c) terfenadine, (d) domperidone, and (e) sertindole. The gray areas are
indicative of the ETPC unbound measured in patients and the black line indicates hERG IC50. Dotted lines indicate the 95% confidence
interval of the fitted curve. ETPC unbound and hERG IC50 data are adapted from Redfern et al., 2003.
112 S.R. Braam et al.higher concentrations (Fig. 5b). Neither of the negative
controls in the assay caused any FPD prolongation.
Discussion
Efficient, reproducible differentiation of hESC to ventricular
cardiomyocytes, preferably phenotypically similar to adult
human cardiomyocytes, is of critical importance for imple-
menting hESC-CM technologies in drug cardiotoxicity screen-
ing. Previously we have shown that the hESC-END-2 coculture
system is a very efficient and reproducible method for
cardiac lineage differentiation, in particular to ventricular-
like cells. Here we show that these cardiomyocyte popula-
tions are phenotypically homogeneous, have strong electro-physiological responses, and are suitable for drug safety
pharmacology.
Previously, we and others have discussed the immaturity
of hESC-CM compared to the human adult heart (Denning and
Anderson, 2008; Mummery et al., 2003; Passier et al., 2008;
Satin et al., 2004) . In a previous study we disaggregated
beating areas that had formed during 12 days of differenti-
ation and found by patch clamp electrophysiology that the
cells were comparable to 16-week fetal ventricular cardio-
myocytes (Mummery et al., 2003). One of the major
differences between hESC-CM and mature cardiomyocytes
is their relatively low resting potential. This means that
Nav1.5 sodium channels can be spontaneously activated
resulting in AP generation (Satin et al., 2004). Finally, the
Figure 5 hESC-CM responses of drugs not associated with TdP.
FPD–dose relationship for hESC-CM in the presence of increasing
amounts of (a) ketoconazole, and (b) verapamil. The gray areas
indicate the ETPC unbound measured in patients and the black
line indicates hERG IC50. Dotted lines indicate the 95%
confidence interval of the fitted curve. ETPC unbound and
hERG IC50 are adapted from Redfern et al., 2003.
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a lower INa current compared to adult cardiomyocytes.
Importantly, chronotropic responses of dissociated hESC-CM
are comparable to human fetal ventricular cells. This was
demonstrated by decreased beating frequency following
treatment with the cholinergic agonist carbachol, whereas
adrenergic agonists phenylephrine and isoprenaline in-
creased beating frequency (Mummery et al., 2003). Inter-
estingly, despite the relatively immature phenotype of hESC-
CM, we found that the drug responses were highly predictive
of clinically observed cardiotoxic effects. To validate hESC-
CM as a potentially useful new in vitro test system for QT
prolongation and TdP, we performed dose escalation studies
for a number of drugs known to prolong the QT interval as a
therapeutic or side effect. Two previous studies also used
hESC-CM in combination with the MEA system to measure
drug responses (Caspi et al., 2009; Reppel et al., 2005) but
none of them compared a number of compounds systemat-
ically over a wide concentration range in dose-dependent
manner. As a starting point, we used three drugs that block
sodium, calcium, and hERG potassium channels. As expected
lidocaine, a classical sodium channel blocker, caused dose-
dependent cessation of beating at 30–100 μM. Nifidipine, a
classical calcium channel blocker, reduced the FPD in a dose-
dependent fashion and E-4031 increased the FPD by blockingthe hERG channel. Interestingly we observed arrhythmic
behavior in 3 of 4 independent beating areas in response to
high E-4031 concentrations. E-4031 was developed as novel
class III antiarrhythmic but this development was stopped for
reasons that have remained undisclosed. Most importantly,
hESC-CM behavior was reproducible, although a wide variety
of field potential shapes was observed. This illustrates that
hESC-CM as a model can be used to investigate the effects of
drugs on various ion channels present in cardiomyocytes.
Having validated the different ion channel responses, we
then profiled a series of drugs that fell into one of three
categories: (1) repolarization-prolonging antiarrhythmics, (2)
drugs associated with QT prolongation or with TdP as a clinical
side effect, and (3) drugs not associated with QT prolongation
or TdP (negative controls). Quinidine and D,L-sotalol are both
used therapeutically to prolong the QT interval, but are also
strongly associated with arrhythmias. Both D,L-sotalol and
quinidine induced prolongation at concentrations relatively
close to the ETPC unbound. D,L-Sotalol is especially interesting
since the hERG IC50 data (74 uM) are clearly distinct from the
ETPC unbound (1.8–14 μM). Therefore, despite the strong
associationwith QTprolongation andTdP, a conventional hERG
assay would predict no QT effect of the compound at
therapeutic plasma concentrations. Quinidine showed a
massive prolongation of the field potential at concentrations
higher than the ETPC unbound. Quinidine ion channel interac-
tions are known to be complex. In addition to its blocking effect
on hERG, quinidine blocks inward calcium current (ICa), the
rapid (IKr) and slow (IKs) components of the delayed potassium
rectifier current, the inward potassium rectifier current (IKI),
the ATP-sensitive potassium channel (IKATP), and Ito (Nenov et
al., 1998). Furthermore, quinidine-induced INa block has been
shown to increase at higher beating frequencies, dependent on
the ion-channel state (Roden et al., 1987). It has a low affinity
for the resting state, avidly blocks open channels, but does not
bind significantly to inactivated sodium channels (Hondeghem
and Matsubara, 1988; Tsujimae et al., 2004). Nevertheless its
net effect is prolongation of the AP in normal and diseased
hearts, which was clearly shown in the hESC-CM.
Addition of drugs from the second category, domperidone,
sparfloxacin, and cisapride to hESC-CM, had a clear effect on
the FPD interval. Interestingly in contrast to the repolariza-
tion-prolonging drugs tested here the effective concentration
triggering FDP prolongation was always higher than the ETPC
unbound, which might explain the low incidence of TdP in
patients taking these drugs. Although both sertindole and
terfenadine, drugs from the same category, had only minor
effects on the FPD interval this may nevertheless indicate
functional interactions with ion channels. Terfenadine caused
a minor prolongation of the FPD interval followed by a
shortening at higher concentrations. This is in agreement
with guinea pig ventricular myocyte data where terfenadine
has also been described as causing a small, but significant,
prolongation of APD90 at 100 nM and 1 μM at 1 Hz stimulation
frequency, while at higher concentrations, AP duration was
shortened (Terrar et al., 2007). In the same study, dog Purkinje
fibers showed no significant effects after terfenadine admin-
istration (Terrar et al., 2007). In conclusion; we observed FPD
changes for all tested drugs without exception but always at a
higher concentration than the ETPC unbound. This was distinct
from the repolarization-prolonging drugs where we observed
FPD changes at the ETPC unbound. We therefore hypothesize
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induce TdP) can act synergistically with known proarrhythmic
risk factors such as silent mutations, drug–drug interactions,
heart failure, ventricular hypertrophy, hypomagnesemia,
hypokalemia, hypocalcemia, hypoxia, or acidosis. The combi-
nation of any of these factors can induce TdP in patients taking
these medicines (Roden et al., 1996; Roden and Viswanathan,
2005). Finally, addition of the negative control drugs
verapamil and ketoconazole to hESC-CM did not result in FPD
prolongation, as expected. The fact that verapamil did not
prolong the FP interval is of interest since the close margin
between the ETPC unbound (25–81 nM) and the hERG IC50
(140–830 nM) would suggest differently. Therefore verapamil
is a classic “false positive” in a conventional hERG assay.
Previously, an association of 1.93 (95% CI: 1.89–1.98)
between the anti-hERG activity of drugs, measured as log10
(ETCP unbound/IC50), and the reports of serious ventricular
arrhythmias and sudden death to the WHO-UMC database
was found (De Bruin et al., 2005). In another study, a 30-fold
safety margin (between the hERG IC50 and the ETPC
unbound) was established as providing an acceptable degree
of safety (Redfern et al., 2003). Using hERG IC50 as criteria,
both verapamil and sparfloxacin would be classified incor-
rectly. Verapamil was introduced to the market in 1982 and
has not been associated with TdP. This is likely the result of
multiple channel blocks, which compensate the hERG-
blocking effect. In fact we observed a shortening of the
FPD in hESC-CM, which is in agreement with clinical data
(Fauchier et al., 1999). Sparfloxacin has a low proarrhythmic
potential. However, the hERG IC50 and the ETPC unbound
values are in the same concentration range. This would
suggest a strong association with QT prolongation and TdP, as
antiarrhythmic drugs prolonging repolarization. The hESC-
CM model as used here would have accurately predicted the
risk by showing drug-induced QT prolongation but only at
concentrations higher than the ETPC unbound. The data for
both verapamil and sparfloxacin underscore the necessity of
a human model system that displays the full complexity of
the human cardiomyocyte.
In conclusion, our results indicate that electrophysiolog-
ical properties and drug responses of hESC-CM match clinical
observations on QT prolongation/shortening and arrhythmia
at similar concentrations. We showed here that by using FPD
prolongation as a readout hESC-CM flags adverse drug effects
with greater confidence than standard hERG in vitro assays.
Screening a wider variety of drugs under defined conditions
would further validate and identify the strengths and
weaknesses of the system. Ultimately this should lead to
the definition of a safety margin which can be instrumental
for improving preclinical decision making and reducing drug
development costs.Materials and methods
Cell culture and differentiation
HES3 cells (Costa et al., 2005) were routinely cultured on
129SV mouse embryonic fibroblast (MEFs) to maintain
pluripotency and induced to differentiate to cardiomyocytes
as described previously (Mummery et al., 2003; Passier et al.,
2005). Large numbers of contracting areas are obtainedwithin 12 days that routinely consist of 20–25% cardiomyo-
cytes and 75–80% endodermal cells and other mesodermal
derivatives but no neural cells.
Patch clamp electrophysiology
Patch clamp electrophysiology was essentially done as
described previously (Graichen et al., 2008; Moore et al.,
2005). Briefly, beating clumps of cardiomyocytes were
dissociated using a collagenase-based method. Cardiomyo-
cytes were plated on gelatin-coated glass and measured
between 7 and 14 days after plating. Microelectrodes with a
resistance between 1 and 3 MΩ were made from borosilicate
glass (Clark Electrical Instruments, GC-150 T) with a Flaming/
Brown Micropipette Puller Model 80 (Sutter Instruments, CA).
During electrophysiological measurements they were kept in
a DMEM/F12-basedmediumwithout serum or phenol red. The
pipette contained buffer consisting of 145 mM KCl, 5 mM
NaCl, 2 mMCaCl2, 4mM EGTA, 2mMMgCl2, and 10mMHEPES,
adjusted to pH 7.30 with KOH.
MEA electrophysiology
MEA chips were plasma-cleaned and coated with fibronectin
for 1 h at 37 °C. Clumps of beating hESC-CM clusters were
microdissected and replated on standard 60 electrode MEAs
or alternatively 6-well MEAs. Extracellular recording was
performed using a MEA1060INV MEA amplifier (Multi Channel
Systems, Reutlingen, Germany). Output signals were digi-
tized at 10 kHz by use of a PC equipped with a MC-card data
acquisition board (Multi Channel Systems). Standard mea-
surements were performed in DMEM supplemented with 5%
FCS. During recordings, temperature was kept at 37 °C. Data
were recorded using QT-screen (Multi Channel Systems,) and
analyzed off-line with QT-analyzer (Multi Channel Systems).
Data processing
Field potential duration or sodium amplitude data from at
least three independent beating areas were averaged using
GraphPad Prism software. Datapoints are displayed as
mean±SEM. Curves were fitted using the one phase decay
algorithm; 95% confidence intervals are plotted as dashed
lines.
Compounds
Lidocaine, nifedipine, E-4031, cisapride monohydrate, quin-
idine and verapamil hydrochloride, D,L-sotalol, sparfloxacin,
sertindole, terfenadine, domperidone, and ketoconazole
were obtained from Sigma-Aldrich. The substances were
dissolved DMSO at 10 mM and serial dilutions were made in
medium. The highest concentration of DMSO is reached at
30 μM drug which represents 0.3% DMSO. Measurements were
started after a wash-in time of 2 min.Acknowledgments
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